James N. Cooper, M.D. – Chairman of the Board
Dr. Cooper is currently Director of Medical Research Development and Professor of Life Sciences at George Mason University. Previously, he was Assistant Dean and Professor of Medicine at the Georgetown University School of Medicine, as well as Professor of Medicine at the Virginia Commonwealth University. He also served as Chairman of the Department of Medicine at Inova Fairfax Hospital and was Inova Health Systems Medical Director of Research and Education. During his tenure there, multiple specialties within his department were cited in US News and World Report’s annual list of top hospital programs. Dr. Cooper has over 25 years of experience in clinical research and has presented scientific papers and authored multiple publications. He received his BA from Columbia University and an MD from New York University, as well as obtaining additional training at Georgetown University Hospital, Boston City Hospital and the University of Chicago. He also completed the Management Development Program for Physician Executives at The University of Pennsylvania’s Wharton School of Business.
Glenn D. Hoke, Ph.D. – President and Chief Executive Officer
Dr. Hoke joined Theranostics Health as its President and Chief Operating Officer in September, 2009 before being promoted to President and Chief Executive Officer in 2010. Dr. Hoke is responsible for the managing the Company’s operations, fundraising, and strategic direction. He has served on the Board of Directors at his prior position as Executive Vice President and Chief Scientific Officer while at Dyad Pharmaceutical Corporation (2003-2009). At Dyad, he managed the preclinical development of the company’s lead therapeutics, Prior to Dyad, while Vice President Research and Development at Gene Logic, Inc. (1998-2003), Dr. Hoke led research and development efforts on a number of platform technologies. Prior to Gene Logic, he was Vice President at Genetic MediSyn (1993-1998), the drug discovery arm of SyntheCell. Before Genetic MediSyn, Dr. Hoke was employed at Isis Pharmaceuticals (1989-1993). Prior to his tenure at Isis, he worked as a joint appointee in the Departments of Molecular Pharmacology and Investigative Toxicology at SmithKline and French Research Laboratories (1986-1989). Dr. Hoke received his doctorate (1986) Biochemistry at the Medical College of Virginia, Virginia Commonwealth University; a B.S. in biology (1974) from Virginia Polytechnic Institute and State University; and a master’s degree in biology (1979) from Virginia Commonwealth University.
Joseph S. Bailes, M. D.
Dr. Bailes is a medical oncologist with substantial experience in legislation, public policy and advocacy, as well as the business aspects of the practice of oncology and medicine. Dr. Bailes has served in various executive leadership capacities for the American Society of Clinical Oncology (ASCO), including terms as President, Interim Executive Vice President and Chief Executive Officer, and Chair of the ASCO Government Relations Council. He has also served as the Executive Vice President of Clinical Affairs for US Oncology, Inc. Prior to that, Dr. Bailes was Executive Vice President and National Medical Director of Physician Reliance Network, Inc (PRN), one of the corporate predecessors to US Oncology. Dr. Bailes has many years of experience in the practice of oncology in the private sector, he is a partner in Texas Oncology, P.A., the largest oncology practice group in the country, and he was a founding member of PRN. Dr. Bailes received his medical degree from the University of Texas Southwestern Medical School at Dallas, followed by his internship and residency at Parkland Memorial Hospital in Dallas. He completed his Medical Oncology/Hematology Fellowship at the University of Texas Health Science Center in San Antonio.
Eric M. Eastman, Ph.D.
Dr. Eric Eastman is currently the Chief Science Officer of DioGenix, Inc. and a strategic business consultant to select biotechnology and biopharmaceutical companies. He was previously Vice President for Diagnostic Ventures at Gene Logic, Inc. He has 27 years of research and management experience in the biotechnology and biopharmaceutical industry. Dr. Eastman has held various senior management positions including Chief Scientific and Operations Officer for Genetraks Holdings, based in Brisbane, Australia; Senior Vice President, Chief Scientific Officer and SAB Chairman for MetriGenix Corporation (now Xceed Molecular) in Toronto, Canada; President of Morphochem, Inc. (the U.S. subsidiary of Morphochem AG, headquartered in Munich Germany); Senior Vice President and Chief Technology Officer at Gene Logic, Inc.; Director, Gene Expression and Process Research & Development at GeneMedicine, Inc. (now Valentis, Inc); Vice President and Chief Scientific Officer of Lark Sequencing Technologies, Inc. (now Cogenics, a division of Clinical Data Inc.); and Director of Molecular Biology and Immunoassay Development at BIOTX, Inc. Dr. Eastman received his M.Phil. and Ph.D. degrees in Human Genetics and Development from Columbia University College of Physicians & Surgeons and did his post-doctoral training in the Department of Cell Biology at Baylor College of Medicine. Dr. Eastman also received a B.A. degree in Biology from Middlebury College and an M.S. degree in Genetics and Cell Biology from the University of Connecticut. Dr. Eastman has served on various Boards of Directors and currently serves on various scientific advisory boards for U.S.-based and International biotechnology companies.
William D. King
Mr. King has held several executive positions including CEO of Aviation Distributors Inc., a consultant to McCrory Corp. providing successful turnaround guidance for McCrory Stores, Executive Vice President and President of the Electrical and Mechanical Groups of JWP, Inc. and President and Chief Operating Officer of International Technology Corporation. Mr. King began his career as a Senior Consultant with McKinsey and Company, Inc. in 1969 after graduating from Harvard Business School. He graduated from the University of North Carolina in 1964 and served as a Captain in the U. S Marine Corps.
Kevin G. Quinn
President of Wye River Group, Mr. Quinn has over 30 years of corporate and project finance experience. From 1979 to 1982, Mr. Quinn was an attorney at Miles & Stockbridge in Baltimore. From 1982 to 1994, Mr. Quinn was employed as an investment banker at Alex. Brown & Sons, where he progressed from the positions of Associate to Managing Director, and served during his last four years there as head of the firm’s Public Finance Department. In 1994, Mr. Quinn became Managing Director and head of Investment Banking for H.C. Wainwright & Co. in Boston. During his tenure at Alex. Brown and Wainwright, Mr. Quinn also served as lead banker or advisor on over 200 engagements comprising public and private offerings of equity and debt securities, mergers and acquisitions and divestitures. In 1999, Mr. Quinn launched Wye River Group which focuses on providing financial advisory, capital financing and investment advisory services to institutional clients. Mr. Quinn is a graduate of the University of Maryland Business School (MBA), University of Maryland Law School and Loyola College (BA). In addition to his activities at Wye River Group, Mr. Quinn serves on the boards of directors of CareFirst, Inc. (Blue Cross/Blue Shield) and Securities Finance Trust Company. He has previously served on the boards of Merge Healthcare (NASDAQ: MRGE) and Old Mutual Asset Management Trust Company.
Barry S. Strauch, M. D.
Dr. Barry S. Strauch has been an active member of the medical staff at Inova Fairfax Hospital for 37 years, serving for 24 years as Chief of the Nephrology Section and for the past five and a half years as Interim Chairman of the Department of Medicine. Dr. Strauch co-founded and served as Chairman of Washington Nephrology Associates, a regional practice and one of the two largest nephrology practices in the United States. He served as Chairman of a quasi-government agency (one of 32 networks in the United States) which regulated quality and need for dialysis and transplantation and as a member of the executive committee of the national forum of such networks. Dr. Strauch has been an active clinical teacher in both general Internal Medicine and Nephrology, and has published a significant number of papers investigating research topics in dialysis grafts and transplant rejection. He won the Vernon K. Vance, M.D. Memorial Award for long-standing teaching excellence. He currently serves as Clinical Professor of Medicine at the Medical Schools of Georgetown, George Washington, and Virginia Commonwealth University and as a trustee on the Board of Johns Hopkins Medicine. He has previously served on the Board of Vapotherm. He is the recipient of the 2009 Laureate Award by the Virginia branch of the American College of Physicians for long-term contributions to the field of Internal Medicine. Dr. Strauch attended the Johns Hopkins University Medical School and later completed his training in Internal Medicine and Metabolism at Yale and N.I.H.